Our findings elucidate the importance of the P4HA1‐P4HA2‐PI3K‐AKT axis in CRC and identify P4HA1 as a promising therapeutic target to impede CRC growth and metastasis while altering the tumor immune landscape. The gene discussed is P4HA2; the disease is neoplasm.